Clinical trials: Eye Cancer
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body.
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
- Trial name
- NBM-BMX-UM (NCT07136181)
- Testing
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Uveal Melanoma
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma.
- Trial name
- NCT01430416
- Testing
- AEB071
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Cervical Cancer, Gastric Cancer
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
- Conditions
- Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT03652077
- Testing
- INCAGN02390
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Uveal Melanoma, Ocular Melanoma
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma.
- Trial name
- OCULE-01 (NCT06717126)
- Testing
- roginolisib, Investigator choice of standard therapy
- Where
- 16 sites in Italy, Spain and 1 more
- Volunteers
- 85 people
- Sponsor
- iOnctura
Metastatic Uveal Melanoma
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with…
- Trial name
- NCT05415072
- Testing
- DYP688
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Myasthenia Gravis
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.
- Trial name
- MyVisionXT (NCT07465289)
- Testing
- Rozanolixizumab
- Where
- 7 sites in United States, China and 2 more
- Volunteers
- 100 people
- Sponsor
- UCB Biopharma SRL
Uveal Melanoma
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma.
- Trial name
- NCT01801358
- Testing
- AEB071, MEK162
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Tumor, Facial Fracture
A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.
This study will address medical devices manufactured by Biomet Microfixation (d.b.a. Zimmer Biomet) designed for fixation and stabilization of the facial and mandibular skeleton.
- Conditions
- Tumor, Facial Fracture, Mandibular Fractures, Fibrous Dysplasia
- Trial name
- NCT04931056
- Testing
- Titanium Facial Plates, Titanium Mandibular Plates, Add-on Condyle
- Where
- Argentina
- Volunteers
- 91 people
- Sponsor
- Zimmer Biomet
Choroidal Melanoma, Indeterminate Lesions
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial.
- Trial name
- CoMpass (NCT07338968)
- Testing
- Observational
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Aura Biosciences
CMV Retinitis
Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
The goal of this exploratory clinical study is to evaluate the safety and efficacy of Cytomegalovirus-Specific T cells (LB-DTK-CMV) to treat patients diagnosed with antiviral-resistant and refractory cytomegalovirus retinitis.
- Trial name
- NCT07679412
- Testing
- LB-DTK-CMV
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- LucasBio
Myopia, Myopia, Moderate
Software Refraction With Mobilerone Versus Retinoscopy
Software refraction in the mobilerone for myopia and astigmatism is a novel medical device for myopia adults and elder children with or without astigmatism.
- Conditions
- Myopia, Myopia, Moderate, Astigmatism
- Trial name
- SRMR (NCT06059521)
- Testing
- Software refraction with Eye Test Technology in a mobilerone, Retinoscopy
- Where
- 3 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Chalazion
Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion
To study the effectiveness and safety of IPL treatment for Chalazion
- Trial name
- NCT07039461
- Testing
- OptiLIGHT
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.
Colorectal Neoplasms
Third Eye Panoramic Device Feasibility Evaluation
This study will evaluate the feasibility of using the Third Eye Panoramic device in conjunction with standard colonoscopes in a clinical setting.
- Trial name
- NCT02368977
- Testing
- Third Eye Panoramic device
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Avantis Medical Systems
Myasthenia Gravis
The Impact of Myasthenia Gravis in the Real World
An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's…
- Trial name
- NCT04176211
- Where
- United Kingdom
- Volunteers
- 2,847 people
- Sponsor
- Vitaccess Ltd
Uveal Melanoma, Ocular Melanoma
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT04417530
- Testing
- AU-011, Suprachoroidal Microinjector, PDT Laser
- Where
- 22 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aura Biosciences
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Infectious Disease, Neoplasms
AnovaOS Network Powered Patient Registry
The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and…
- Conditions
- Infectious Disease, Neoplasms, Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89), Endocrine, Nutritional and Metabolic Diseases (E00-E89)
- Trial name
- NCT05013944
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Anova Enterprises, Inc
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals